$PTGX on NASDAQ
March 11, 2024
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
March 06, 2024
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
February 27, 2024
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 21, 2024
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
February 20, 2024
Protagonist Therapeutics Reports Granting of Inducement Awards
December 13, 2023
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
December 12, 2023
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
December 12, 2023
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
November 27, 2023
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
November 16, 2023
Protagonist Therapeutics Reports Granting of Inducement Awards
November 09, 2023
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)
November 02, 2023
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting
November 01, 2023
Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis
November 01, 2023
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
October 30, 2023
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
October 09, 2023
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
October 03, 2023
Protagonist Therapeutics Reports Granting of Inducement Award
September 05, 2023
Protagonist Therapeutics to Present at Upcoming Investor Conferences
August 16, 2023
Protagonist Therapeutics Reports Granting of Inducement Award
August 09, 2023
Protagonist Receives $34 Million from Warrant Exercises
August 03, 2023
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
July 18, 2023
Protagonist Therapeutics Reports Granting of Inducement Award
July 04, 2023
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
June 09, 2023
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PV
June 06, 2023
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
June 01, 2023
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
May 12, 2023
Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
May 11, 2023
Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
May 11, 2023
Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
May 04, 2023
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 04, 2023
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
April 04, 2023
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
March 15, 2023
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
March 07, 2023
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
December 21, 2022
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 01, 2022
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
November 16, 2022
Protagonist Therapeutics Reports Granting of Inducement Award
November 08, 2022
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting
November 02, 2022
Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer
September 20, 2022
Protagonist Therapeutics Reports Granting of Inducement Award
August 04, 2022
Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 19, 2022
Protagonist Therapeutics Reports Granting of Inducement Award
June 01, 2022
Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
May 26, 2022
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
May 04, 2022
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
April 25, 2022
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
April 19, 2022
Protagonist Therapeutics Reports Granting of Inducement Awards
- No Recent Filings Found.
